These findings not only have important implications in clinical management but may reflect biological differences in HGSCs based on the consequences of the nature of the TP53 mutation in the cancer sample as also suggested by recent gene expression profiling of ovarian cancer cases, which showed differences in transcriptome profiles in samples stratified based on the absence or the nature of the TP53 mutation [7]. This evidence concerns the gene TP53 and ovarian carcinoma.